Tag: transarterial radioembolization
TARE with Y90 microspheres shows survival benefit and low adverse event...
Etienne Garin (Centre Eugene Marquis, Rennes, France), presenting results from an ad-hoc interim analysis of the PROACTIF trial data, reported that “appropriately selected” patients...
‘A new narrative’: TACE in the age of Y90 and immunotherapy
Hotly debated across the Society of Interventional Oncology (SIO; 25–29 January 2024, Long Beach, USA) annual conference programme, speakers took to the stage to...
Understanding dosimetry in order to develop personalised treatment plans
With transarterial radioembolization, one area that continues to be shrouded in debate is the concept of dosimetry and dose, writes David Liu.
As we develop...
